310 results
Page 6 of 16
6-K
EX-99
ujh77
1 Jun 20
BioLineRx Announces $4.39 Million Registered Direct Offering
8:05am
424B5
mnb4zyb9iu2k0i7v
28 May 20
Prospectus supplement for primary offering
12:00pm
6-K
EX-99
vx0nyyh39k31lrfnz
28 May 20
Current report (foreign)
11:56am
6-K
zvcol7f
28 May 20
Current report (foreign)
11:56am
6-K
EX-99
u1fiimj2
27 May 20
BioLineRx Announces Publication of Data from Ongoing
7:00am
6-K
EX-99
n5slp7u3nliep9dq
26 May 20
BioLineRx Announces $9.0 Million Registered Direct Offering
8:45am
6-K
EX-99
auqakrlsoxr tjjls
20 May 20
BioLineRx Reports First Quarter 2020 Financial Results
7:00am
6-K
EX-99
zfxcmc
12 Mar 20
BioLineRx Reports Year-End 2019 Financial Results
7:00am
6-K
EX-99
9fssjq8prwx 43t
27 Feb 20
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination with The COMBAT/KEYNOTE-202 Study
7:00am
6-K
EX-99
j7g12ma0 gay7yc
22 Jan 20
BioLineRx Completes Recruitment in Triple Combination
7:00am
6-K
EX-99
9ry9c6ntw 5a4
14 Jan 20
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of
7:00am
6-K
EX-99
ou4tzr6h
13 Dec 19
BioLineRx Announces Updated Phase 2a Data from Triple
7:00am
6-K
EX-99
ygnhjbhx 957
5 Dec 19
BioLineRx Announces Preliminary Phase 2a Data from Triple
7:00am
6-K
EX-1
mpwgs4ldflyhbo aewh
12 Nov 19
Current report (foreign)
6:21am
6-K
EX-99
6leo16tjjs4
5 Nov 19
BioLineRx Announces BL-8040 in Combination with KEYTRUDA Shows Clinical Activity in Heavily Pretreated
9:00am
6-K
EX-99
8nhxr i8qxli
5 Nov 19
BioLineRx Presents Preclinical Data from Triple Combination
8:00am
6-K
EX-99
hvo3 5pyp728c7
25 Sep 19
BioLineRx Announces Dosing of First Patient in Part 2 of
7:00am
6-K
EX-99
elu3vx cq1fc11
3 Sep 19
BioLineRx Successfully Completes Dose-Escalation Part of
7:00am